This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • General Rhinology  • Complementary and Alternative Medicine  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Schapowal¹ is to be commended for reporting the results of a carefully conducted 2-week study on the dose-response of butterbur therapy in patients with intermittent allergic rhinitis. The author’s follow-up trial of a previous non–placebo-controlled study² sheds further light into the potential therapeutic role of butterbur in the treatment of allergic airway disease. Recent trials of butterbur in which objective measures were used have consistently shown its beneficial effects. Treatment with butterbur has been found to attenuate the response to nasal provocation testing with adenosine monophosphate compared with placebo in patients with intermittent allergic rhinitis.³ Also, when compared with fexofenadine hydrochloride, a modern histamine H₁-receptor antagonist, butterbur has been demonstrated to confer protection against nasal adenosine monophosphate challenge while improving nasal symptoms in patients with persistent allergic rhinitis.⁴ Importantly, the anti-inflammatory effects of butterbur are not confined only to the upper airway but also extend into the lower airway, . . . [Full Text of this Article]

AUTHOR INFORMATION
Daniel K. C. Lee, MB, BCh, MRCP, MD

RELATED ARTICLE

Addressing the Long-term Safety Aspects of Butterbur Therapy: A Call for Immediate Action—Reply
Andreas Schapowal
Arch Otolaryngol Head Neck Surg. 2005;131(6):540.
EXTRACT | FULL TEXT